drug-related problems they identified. Limitations in the review, in particular marked heterogeneity between studies and a failure to assess study quality, mean that these conclusions should be interpreted with caution.
The included studies were conducted in a wide range of settings that included paediatric units, primary care clinics, longstay geriatric units and anaesthetic departments. Reporting methods varied for each assessment tool (for example, incident reports could be anonymous or not). Types and definitions of medication problems varied and ranged in gravity from omission of documentation to patient injury and were reported as the number of events or the number of opportunities for events. Different units of analysis were used and included beds, patients and patient days. Review outcomes for accuracy included positive predictive values, sensitivity, specificity, false negatives, false positives and inter-rater agreement. The observation period ranged from four months to 34 months (where reported).
Two reviewers independently selected the studies. Disagreements were resolved by consensus.
Assessment of study quality
The authors did not state that they assessed validity.
Data extraction
Two authors independently categorised the studies according to type of assessment tool used in accordance with review definitions. Descriptive data were extracted from the individual studies and recorded in a table of studies. P values for differences between the groups were calculated for some comparisons.
The authors did not state how many reviewers extracted data.
Methods of synthesis
The studies were combined in a narrative synthesis organised by outcomes. 
Results of the review
Twenty-eight studies were included. They apparently included one randomised study, two comparative studies, nine prospective cohort studies, four prospective studies, five retrospective reviews and seven observational studies. The total number of participants included was not reported.
Direct observation identified a larger number of problems than other methods (six studies). Incident report review identified the fewest problems in most comparisons; chart review consistently reported more events compared to incident report review (13 studies). Findings that compared chart reviews versus trigger tools were inconsistent (five studies). Overlap in the identification of events between different methods was rare. Direct observation was the method most likely to identify problems found with other tools; all events detected by incident report reviews or chart review were also detected by direct observation.
Sensitivity, specificity and positive predictive values differed widely between studies reporting these data. Incident report review was more specific than other methods in identifying problems (three studies), but was less sensitive than trigger tools (four studies). The positive predictive value for trigger tools ranged from zero to 100% (six studies) depending on the design of the tool.
Trigger tool was the most time-efficient (two studies) and least labour-intensive assessment method, followed by incident report review and then direct observation (one study).
Other findings were reported in the review.
Cost information
Trigger tools (once fully established) were less expensive than chart review (two studies): US$42.40 per adverse drug reaction using a trigger tool versus $68.70 using chart reviews (one study). Chart review cost $0.63 per drug dose versus $4.82 for direct observation (one study). One study that compared incident report review with trigger tools attributed an annual cost saving of $56,000 to the avoidance of detectable drug-related problems taking the cost of detection into account.
